Ono Pharmaceutical
4528.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥515.8bn | ¥486.9bn | ¥502.7bn | ¥447.2bn | ¥361.4bn | ¥309.3bn |
| Operating income | ¥92.2bn | ¥59.7bn | ¥159.9bn | ¥142.0bn | ¥103.2bn | ¥98.3bn |
| Net income (owners) | ¥69.8bn | ¥50.0bn | ¥128.0bn | ¥112.7bn | ¥80.5bn | ¥75.4bn |
| Total assets | ¥1.11T | ¥1.06T | ¥913.7bn | ¥882.4bn | ¥739.2bn | ¥745.4bn |
| Net assets / equity | ¥856.6bn | ¥788.2bn | ¥798.6bn | ¥747.8bn | ¥661.7bn | ¥639.7bn |
| Operating cash flow | ¥136.8bn | ¥82.5bn | ¥110.7bn | ¥159.6bn | ¥61.8bn | ¥74.0bn |
| EPS (basic) | ¥148.49 | ¥106.55 | ¥266.61 | ¥230.85 | ¥162.19 | ¥151.11 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 212 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 212 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 82 figures · EDINET |
| 2024-04-01 → 2025-03-31 | AnnualAmended | 212 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 212 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 212 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 108 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 108 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 212 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 108 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 108 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 212 figures · EDINET |
21 more reports are still being processed.